EyePoint Pharmaceuticals' stock dropped nearly 80% after its Phase 3 LUCIA trial for DURAVYU failed to meet the primary endpoint in treating wet AMD. The company has since ended its pivotal wet AMD trials early, raising concerns about whether it adequately disclosed material information to investors. Law firm Levi & Korsinsky is investigating potential securities claims and encourages affected shareholders, including those who sold at a loss, to submit their information for possible recovery. No upfront cost or court appearance is required to participate in the investigation.
EyePoint Pharmaceuticals' recent legal investigation news is presented here with Pluang's Health-sector market data as of Oct 22, 2026 21:22 WIB. Among 150 priced Health-sector US stocks tradable on Pluang, 94 rose and 54 fell today. Notable movers include Inovio Pharmaceuticals Inc (INO) at USD 0.86 with a 7.71% increase, 10X Genomics Inc (TXG) at USD 70.65 down 6.54%, and Nuwellis Inc (NUWE) at USD 0.49 down 5.23%.
The global Urban Air Mobility (UAM) market is projected to grow from $2.16 billion in 2026 to $16.27 billion by 2035, at a CAGR of 20.9%. This growth is fueled by rising urbanization, traffic congestion, and advances in electric vertical takeoff and ...
Scotiabank analyst Nat Schindler set a $650 price target for Meta Platforms, about 6.8% below its then-current price of $697.52. Despite Meta's strong revenue from Facebook, Instagram, and WhatsApp, investor concerns over increased artificial intelli...
UBS maintains a Buy rating on Berkshire Hathaway's Class A shares, currently trading near $811,320. The company's diverse portfolio and substantial cash reserves of about $360 billion provide stability and investment flexibility. Investor confidence ...
Barclays PLC reported Q3 2026 earnings with EPS of $0.66 and revenue of $9.86 billion, both slightly below analyst estimates. Pre-tax profit rose 12% year-over-year to £2.32 billion but missed forecasts due to a 19% decline in fixed-income revenue, p...
Comfort Systems USA is set to report strong Q3 2026 results, with analysts predicting earnings of $12.85 per share and revenue around $3.40 billion, driven by high demand in data centers and a record $14.06 billion backlog. The company showed robust ...
